Skip to main content

FDA reapproves gemtuzumab ozogamicin for CD33-positive AML treatment

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
FDA reapproves gemtuzumab ozogamicin for CD33-positive AML treatment

User login

Username

Password

Reset your password

Type	Lead	score